Silence Therapeutics has patented a compound for RNA interference therapy and research purposes, particularly for treating liver disease. The compound consists of a modified saccharide moiety conjugated to a nucleic acid, as outlined in formula (II) of the patent claim. GlobalData’s report on Silence Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Silence Therapeutics, was a key innovation area identified from patents. Silence Therapeutics's grant share as of February 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Compound for rna interference therapy in liver disease
A recently granted patent (Publication Number: US11912993B2) discloses a compound with a specific chemical formula aimed at delivering nucleic acids to hepatocytes. The compound, as described in the claims, includes a saccharide selected from various options such as N-acetyl galactosamine, mannose, and glucose, among others. Additionally, the patent covers the use of this compound in compositions with suitable carriers or excipients for delivery and a method for treating subjects suffering from a range of conditions including liver disease, genetic disease, hemophilia, and metabolic diseases like hypercholesterolemia.
Furthermore, the patent also details an in vitro method for delivering nucleic acids to hepatocytes using the compound, emphasizing its potential applications in treating various diseases and conditions. The method outlined in the patent involves administering the composition containing the compound to subjects in need, particularly those afflicted with liver-related ailments, rare diseases like acromegaly, and metabolic disorders such as dyslipidemia. Overall, the patent highlights the compound's versatility in targeting hepatocytes for nucleic acid delivery and its potential therapeutic benefits across a spectrum of diseases ranging from liver fibrosis to cardiovascular issues and rare genetic disorders.
To know more about GlobalData’s detailed insights on Silence Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
